Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 2/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CCNH | P51946 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375993 | 0.81 | PAK1 (0.51) | ALDH1A1KDM4EPAK1CDK2RXFP1 | |
| SCHEMBL2951841 | 0.81 | PAK1 (0.55) | ALDH1A1KDM4EPAK1CDK2RXFP1 | |
| SCHEMBL10869151 | 0.80 | PAK1 (0.57) | ALDH1A1KDM4EPAK1CDK2RXFP1 | |
| Hydrochloric Acid SCHEMBL6821631 | 0.80 | PAK1 (0.54) | ALDH1A1KDM4EPAK1CDK2RXFP1 | |
| SCHEMBL31380702 | 0.77 | ALDH1A1 (0.45) | ALDH1A1KDM4EPAK1CDK2RXFP1 | |
| SCHEMBL4373719 | 0.76 | HRH3 (0.36) | HRH3CHRNB2CHRNA4HTR3AHRH4 | |
| SCHEMBL18167360 | 0.75 | ALDH1A1 (0.41) | ALDH1A1KDM4EPAK1 | |
| SCHEMBL9854792 | 0.72 | ALDH1A1 (0.46) | ALDH1A1KDM4EPAK1CDK2RXFP1 | |
| SCHEMBL12539876 | 0.71 | TYRO3 (0.46) | SCDCDK7CDK9 | |
| SCHEMBL1378385 | 0.70 | ALDH1A1 (0.47) | ALDH1A1KDM4EPAK1CDK2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1113020-B1 | Nucleosides and oligonucleotides containing boron clusters | UNIV EMORY (US) | 2009-10-28 | — | — | EP | disclosed |
| US-6583122-B2 | Use in boron neutron capture therapy (BNCT) and diagnostic purposes; treating cancer, viral infections such as HIV, hepatitis B virus | EMORY UNIVERSITY | 2003-06-24 | — | — | US | disclosed |
| US-20020160969-A1 | Nucleosides and oligonucleotides containing boron clusters | DEPARTMENT OF VETERANS AFFAIRS | 2002-10-31 | — | — | US | disclosed |
| EP-0731808-B1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | UNIV EMORY (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-1113020-A2 | Nucleosides and oligonucleotides containing boron clusters | EMORY UNIVERSITY (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6180766-B1 | OLIGONUCLEOTIDE WITH UNCHARGED INTERNUCLEOTIDE LINKAGE(S) OF 3',5'-O,O-((CARBORAN-1-YL-METHYL)PHOSPHONATE); MADE BY REACTING O-METHYL(O-CARBORAN-1-YL)METHYL PHOSPHONATE WITH PROTECTED NUCLEOSIDE; USE IN BORON NEUTRON CAPTURE THERAPY | DEPARTMENT OF VETERANS AFFAIRS | 2001-01-30 | — | — | US | disclosed |
| US-5872107-A | ANTICARCINOGENIC AGENTS CAPTURE THERAPY FOR TUMORS | EMORY UNIVERSITY (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0788364-A4 | TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY | UNIV EMORY (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0788364-A1 | TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY | EMORY UNIVERSITY (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0731808-A4 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | UNIV EMORY (US) | 1997-04-02 | — | — | EP | disclosed |
| US-5599796-A | USING BORON CLUSTER-CONTAINING NUCLEOSIDES OR OLIGONUCLEOTIDES; PARTICULARLY EFFECTIVE FOR BLADDER, PROSTATE AND KIDNEY | EMORY UNIVERSITY (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0731808-A1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | EMORY UNIVERSITY (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996014073-A1 | TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY | EMORY UNIVERSITY (US) | 1996-05-17 | — | — | WO | disclosed |
| WO-1995015333-A1 | NUCLEOSIDES AND OLIGONUCLEOTIDES CONTAINING BORON CLUSTERS | EMORY UNIVERSITY (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160969-A1 | Nucleosides and oligonucleotides containing boron clusters | NUDT1, NTPCR, NAMPT | ALDH1A1 4697/4885KDM4E 4815/4885PAK1 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.